Pacific Biosciences Of California (PACB) Gross Margin Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,021.00 |
| Dec 31, 2025 | -491.00 |
| Sep 30, 2025 | 435.00 |
| Jun 30, 2025 | -180.00 |
| Mar 31, 2025 | -5,170.00 |
| Dec 31, 2024 | -2,066.00 |
| Sep 30, 2024 | -652.00 |
| Jun 30, 2024 | -2,256.00 |
| Mar 31, 2024 | -208.00 |
| Dec 31, 2023 | -1,303.00 |
| Sep 30, 2023 | 1,457.00 |
| Jun 30, 2023 | -839.00 |
| Mar 31, 2023 | -1,259.00 |
| Dec 31, 2022 | -1,928.00 |
| Sep 30, 2022 | 699.00 |
| Jun 30, 2022 | 580.00 |
| Mar 31, 2022 | 680.00 |
| Dec 31, 2021 | 233.00 |
| Jun 30, 2021 | -637.00 |
| Mar 31, 2021 | -494.00 |
| Dec 31, 2020 | -3,093.00 |
| Sep 30, 2020 | -1,005.00 |
| Jun 30, 2020 | -1,944.00 |
| Mar 31, 2020 | 1,442.00 |
| Dec 31, 2019 | 2,005.00 |
| Sep 30, 2019 | -3,227.00 |
| Jun 30, 2019 | 1,168.00 |
| Mar 31, 2019 | 817.00 |
| Dec 31, 2018 | -549.00 |
| Sep 30, 2018 | 85.00 |
| Jun 30, 2018 | 2,356.00 |
| Mar 31, 2018 | 2,101.00 |
| Dec 31, 2017 | 2,741.00 |
| Sep 30, 2017 | 2,810.00 |
| Jun 30, 2017 | 3,609.00 |
| Mar 31, 2017 | 3,738.00 |
| Dec 31, 2016 | 3,958.00 |
| Sep 30, 2016 | 1,642.00 |
| Jun 30, 2016 | -406,276.00 |
| Mar 31, 2016 | -5,031.00 |
| Dec 31, 2015 | -2,705.00 |
| Sep 30, 2015 | -5,293.00 |
| Jun 30, 2015 | -4,183.00 |